GRANULES vs SUPRIYA: Stock Comparison

Granules India Limited vs Supriya Lifescience Limited

Live data: 28 July 2026, 4:08 PM IST • Source: NSE and company filings

Granules India Limited is the larger company by market capitalisation. Granules India Limited shows a lower P/E and a higher dividend yield, while Supriya Lifescience Limited shows a higher ROE, faster revenue growth and lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Granules India Limited and Supriya Lifescience Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, GRANULES is more favourable on 4 of 13 scored metrics and SUPRIYA on 9These counts are context-free and are not an overall rating.

Key Differences

Market Cap
GRANULES is the larger company
₹20,94,875.17 L Cr vs ₹6,689 Cr
P/E Ratio
GRANULES has a lower P/E
31.63x vs 31.98x
P/B Ratio
GRANULES has a lower P/B
4.16x vs 5.58x
EPS
GRANULES has higher earnings per share
₹26.97 vs ₹25.94
Dividend Yield
GRANULES has a higher dividend yield
0.21% vs 0.11%
Revenue Growth (TTM YoY)
SUPRIYA has faster revenue growth
50.2% vs 22.8%
EPS Growth (TTM YoY)
SUPRIYA has faster EPS growth
46.7% vs 31.3%
Qtr Sales Growth
SUPRIYA has stronger quarterly sales growth
50.2% vs 22.8%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricGRANULESSUPRIYA
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricGRANULESSUPRIYA
Live Price₹845.4₹830.1
Day Change0.31%-1.75%
Volume7.05 L92,852
52-Week High₹910₹1,085
52-Week Low₹432.6₹545.5
Distance from 52W High-7.1%-23.49%

Valuation

MetricGRANULESSUPRIYA
Market Cap₹20,94,875.17 L Cr₹6,689 Cr
P/E Ratio31.63x31.98x
P/B Ratio4.16x5.58x
EPS₹26.97₹25.94
Book Value₹205.21₹148.77
Dividend Yield0.21%0.11%

Growth

MetricGRANULESSUPRIYA
Revenue Growth (TTM YoY)22.8%50.2%
EPS Growth (TTM YoY)31.3%46.7%
Qtr Sales Growth22.8%50.2%
Qtr Profit Growth44.6%47.3%

Profitability & Leverage

MetricGRANULESSUPRIYA
ROE13.7%19.1%
ROCE15.5%25.1%
Net Margin11.15%25.26%
Operating Margin22.1%35.5%
Debt to Equity0.3x0x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricGRANULESSUPRIYA
Promoter Holding37.67%68.3%
FII Holding17.5% 2.19 pp6.19% 1.03 pp
DII Holding16.11% 0.9 pp5.3% 0.4 pp
Public Holding28.38% 1.28 pp20.21% 0.63 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Granules India Limited and Supriya Lifescience Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.